Trial reportWorld journal of gastroenterology2023
Efficacy and dose response of
Trial report in World journal of gastroenterology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 2 syntheses or guidelines pooled it, 17 citations in OpenAlex.
- Efficacy of Specific Probiotic Strains in Subtypes of Irritable Bowel Syndrome: Systematic Review and Meta-Analysis of Randomized Controlled Trials.Medicina (Kaunas, Lithuania) · 2025Pooled it
- Unlocking the potential of probiotic administration in caries management: a systematic review.BMC oral health · 2024Pooled it
- Evaluation of the Safety and Impact of Heat-TreatedJournal of microbiology and biotechnology · 2024Trial
- Lactobacillus plantarum in the Treatment of Cancers: A Review.Current microbiology · 2026Review
- Strain-Specific Systematic Review with Meta-Analysis of Probiotics Efficacy in the Treatment of Irritable Bowel Syndrome.Journal of clinical medicine · 2026Review
- Swine-Derived Probiotics and Their Metabolites as an Alternative to Veterinary Antibiotics.Veterinary sciences · 2025Review
- Strain-Specific Therapeutic Potential ofNutrients · 2025Article
- Dietary Modulation of the Immune System.Nutrients · 2024Review
- A Review of Pharmacologic and Non-Pharmacologic Therapies in the Management of Irritable Bowel Syndrome: Current Recommendations and Evidence.Journal of clinical medicine · 2024Review
- Probiotics and Prebiotics for the Treatment of Irritable Bowel Syndrome-A Narrative Review.Journal of clinical medicine · 2024Review
- Complete genome sequence and anti-obesity potential ofFrontiers in microbiology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundProbiotics have shown promise in alleviating symptoms of diarrhea-predominant irritable bowel syndrome (IBS-D); however, the certainty of evidence is low. Well-powered randomized controlled dose-ranging trials are warranted on promising single-strain candidates.
aimTo investigate the clinical efficacy of
methodsThis is a randomized, double-blind, placebo-controlled, multi-center, and dose-ranging study. Three hundred and seven adults, 18-70 years of age, with IBS-D, according to Rome IV criteria, were allocated (1:1:1) to receive placebo or
resultsIBS-SSS was significantly reduced, after 8 wk, in participants receiving
conclusion
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.